Compare ALAR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALAR | NSRX |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | Israel | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 53.5M |
| IPO Year | 2018 | N/A |
| Metric | ALAR | NSRX |
|---|---|---|
| Price | $7.39 | $4.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $27.00 | $20.50 |
| AVG Volume (30 Days) | ★ 30.1K | 3.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.17 | N/A |
| Revenue Next Year | $30.14 | N/A |
| P/E Ratio | $44.31 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.45 | $3.99 |
| 52 Week High | $18.00 | $9.99 |
| Indicator | ALAR | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 41.33 |
| Support Level | $7.27 | N/A |
| Resistance Level | $7.75 | $6.39 |
| Average True Range (ATR) | 0.44 | 0.70 |
| MACD | 0.15 | 0.01 |
| Stochastic Oscillator | 64.74 | 35.08 |
Alarum Technologies Ltd is a software-as-a-service (SaaS) provider operating mainly in the web data collection market, offering web data collection and a private internet browsing platform. The company's Web Data Collection products offer secure, fast, and anonymous IP Proxy Network Solutions & Services, or IPPN or IPPN Solutions, to its business customers which, in turn, enables them to anonymously and securely browse the internet as well as to collect data from any publicly available source on the web, for their business purpose. The company operates in one segment, which is web data collection. Geographically, it derives maximum revenue from United Arab Emirates, followed by China, the United States, Europe, Asia-Pacific, U.K. Virgin Islands, Middle East and Africa, and other regions.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.